CYP2D6 and depressive disorder: Similar trends were noted by a recent sub-analysis by Ruaño et al. (2021), in which they observed LOS to be significantly shorter (mean difference of 2 days) among sub-functional patients in group G compared to S. These findings suggest that using PGx clinical decision support to manage depression can help to reduce overall healthcare expenditures associated with LOS, particularly for CYP2D6 PMs who are at increased risk for adverse effects when receiving treatment with medications metabolized predominantly by CYP2D6 (Maciel et al., 2018; Martin et al., 2019).